Imunon
NASDAQ: IMNNLawrenceville, US · Delaware corporation
Imunon develops nucleic acid-based (DNA) immunotherapies and vaccines, including anti-cancer therapies and vaccines for infectious diseases and cancer. The company builds proprietary immunology and DNA-based platforms aimed at difficult-to-treat conditions.
Founders & leadership
DG
David GaieroExecutive
MT
Michael TardugnoExecutive
KA
Khursheed AnwerExecutive
SL
Stacy LindborgExecutive
NB
Nicholas BorysExecutive
JW
Jeffrey W. ChurchExecutive
MH
Michael H. TardugnoNamed on SEC filing
FJ
Frederick J. FritzNamed on SEC filing
ME
Max E. LinkNamed on SEC filing
Board
FF
Frederick FritzBoard director
DB
Donald BraunBoard director
JD
James DentzerBoard director
Funding
SEC filings, press & company announcements$36.8M disclosed across 5 rounds · 2014–2026
- $10MraisedJun 2026 · 2 sourcesSource ↗
▶$3.3MraisedMay 2025 · 3 investors · BiotechnologyRule 506(b)
▶$3.3MraisedMay 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David GaieroExecutive Officer
- James E. DentzerDirector
- Donald P. BraunDirector
- Michael H. TardugnoExecutive Officer, Director
- Frederick J. FritzDirector
- Stacy R. LindborgExecutive Officer, Director
- Christine PellizzariDirector
- Douglas FallerExecutive Officer
- Susan EylwardExecutive Officer
- Khursheed AnwerExecutive Officer
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- Sales commissions
- $227.5K
- Placement agents
- Brookline Capital Markets, a division of Arcadia Securities, LLC, H.C. Wainwright & Co., LLC
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedAug 2024 · 4 investors · BiotechnologyRule 506(b)
▶$10MraisedAug 2024 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frederick FritzDirector
- Donald BraunDirector
- David GaieroExecutive Officer
- James DentzerDirector
- Michael TardugnoExecutive Officer
- Khursheed AnwerExecutive Officer
- Christine PellizzariDirector
- Stacy LindborgExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $700K
- Placement agents
- H.C. Wainwright & Co., LLC, Brookline Capital Markets
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedJun 2015 · 3 investors · PharmaceuticalsRule 506(b)
▶$5.1MraisedJun 2015 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Frederick J. FritzDirector
- Khursheed AnwerExecutive Officer
- Alberto MartinezDirector
- Augustine ChowDirector
- Robert W. HooperDirector
- Michael H. TardugnoExecutive Officer, Director
- Nicholas BorysExecutive Officer
- Jeffrey W. ChurchExecutive Officer
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- Finders' fees
- $561.8K
- Placement agents
- Maxim Group LLC
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.5MraisedJun 2014 · 1 investors · PharmaceuticalsRule 506(b)
▶$8.5MraisedJun 2014 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas BorysExecutive Officer
- Robert W. HooperDirector
- Michael H. TardugnoExecutive Officer, Director
- Augustine ChowDirector
- Frederick J. FritzDirector
- Jeffrey W. ChurchExecutive Officer
- Khursheed AnwerExecutive Officer
- Alberto MartinezDirector
- Max E. LinkDirector
- Offering amount
- $8.5M
- Amount sold
- $8.5M
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapRegeneron NASDAQ: REGN www.regeneron.com31 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Robinhood27 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Imunon for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Imunon do?
- Imunon develops nucleic acid-based (DNA) immunotherapies and vaccines, including anti-cancer therapies and vaccines for infectious diseases and cancer. The company builds proprietary immunology and DNA-based platforms aimed at difficult-to-treat conditions.
- How much funding has Imunon raised?
- Imunon has disclosed $36.8M raised across 5 rounds.
- Where is Imunon headquartered?
- Imunon is headquartered in Lawrenceville, US.